SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Reduction in Anemia

SOLIRIS significantly improves anemia, and stabilizes hemoglobin levels1-3

In clinical trials, SOLIRIS significantly increased the number of PNH red blood cells and stabilized hemoglobin levels2

Reduction in Anemia

Reduction in Anemia

  • SOLIRIS® (eculizumab) resulted in a 68% increase in the number of PNH red blood cells, with 49% of treated patients maintaining their hemoglobin levels without transfusions1-3
    • Stabilization of hemoglobin did not occur in any placebo-treated patient

Next: Transfusion Reduction

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. SOLIRIS® prescribing information. Alexion Pharmaceuticals, Inc. 2007.
2. Data on File. Alexion Pharmaceuticals, Inc.
3. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.